LABU240802C151000
- 0.90
- -0.40-30.77%
Direxion Daily S&P Biotech Bull 3x Shares ETF Newsroom
United Therapeutics Analyst Ratings
Ladenburg Thalmann Downgrades United Therapeutics to Neutral From Buy, $319 Price Target
BofA Securities Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $88
Analysts' Opinions Are Mixed on These Healthcare Stocks: GE Healthcare Technologies Inc (GEHC), United Therapeutics (UTHR) and Exact Sciences (EXAS)
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Terns Pharmaceuticals (TERN) and Stryker (SYK)
Incyte's Strong Product Performance and Growth Trajectory Merit a Buy Rating
TD Cowen Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $80
Strong Q2 Performance and Growth Trajectory Justify Buy Rating for Exact Sciences
Citigroup Maintains Buy on Incyte, Raises Price Target to $88
TD Cowen Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $350
HSBC Adjusts Price Target on AbbVie to $215 From $185
JPMorgan Adjusts Price Target on Incyte to $61 From $59
A Quick Look at Today's Ratings for Incyte(INCY.US), With a Forecast Between $80 to $88
Analysts Offer Insights on Healthcare Companies: Tilray (TLRY), Day One Biopharmaceuticals (DAWN) and Incyte (INCY)
Oppenheimer Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Truist Financial Sticks to Its Buy Rating for Incyte (INCY)
Incyte Analyst Ratings
B of A Securities Maintains Neutral on Incyte, Raises Price Target to $66
Incyte (INCY) Gets a Buy From Piper Sandler
Analysts' Opinions Are Mixed on These Healthcare Stocks: Incyte (INCY), Genmab (GMAB) and Penumbra (PEN)